Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

著者: Christoph Schmid, Liesbeth C. de Wreede, Anja van Biezen, Jürgen Finke, Gerhard Ehninger, Arnold Ganser, Liisa Volin, Dietger Niederwieser, Dietrich W. Beelen, P Alessandrino, Lothar Kanz, Michael Schleuning, Jakob Passweg, Hendrik Veelken, Johan Maertens, Jan J. Cornelissen, Didier Blaise, Martin Gramatzki, Nöel Milpied, Ibrahim Yakoub‐Agha, Ghulam Mufti, Montserrat Rovira, Renate Arnold, Théo de Witte, Marie Robin, Nicolaus Kröger - Haematologica 2017 被引用: 128

No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1–5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8–21.2%). Shorter remission after transplantation (P